Medicare deploys AI to catch fraud—but beneficiaries may not understand the algorithm

What it does

This bill creates a 2-year pilot program in Medicare that uses artificial intelligence algorithms to score the risk of fraud in claims for durable medical equipment and lab tests on a scale of 1–99. Beneficiaries who opt in will receive alerts when their transactions are flagged as high-risk, and they can respond to dispute the claim; Medicare staff will then review the flagged transaction. The program aims to catch fraudulent billing patterns while giving beneficiaries a chance to verify their own claims are legitimate.

Why we flagged it

The bill's core function is to establish a time-limited AI-driven fraud-detection system for a subset of Medicare claims. It is neither a broad regulatory overhaul nor a narrow carve-out, but a targeted pilot with explicit safeguards and beneficiary opt-in.

What the text implies

• Algorithm training on beneficiary data may create a permanent dataset that outlives the 2-year pilot, with unclear governance over future use or retention.
• The bill permits the Secretary to 'waive or forgo notice' to beneficiaries or providers in some cases, creating a discretionary exception to transparency that is not further defined.
• Beneficiaries who do not opt in receive no fraud protection from this system, potentially creating a two-tier Medicare population with different oversight levels.
• The algorithm's 'learning' mechanism is not subject to external audit or public reporting requirements, limiting accountability for bias or error rates.
• Automatic card termination authority granted to the Secretary may disrupt beneficiary access to care if triggered incorrectly, with no explicit timeline for reinstatement.

Who it affects

Beneficiaries gain transparency and a dispute mechanism for flagged claims, potentially protecting them from fraud and billing errors. However, the algorithm's decision-making process is opaque, beneficiaries must opt in to participate, and the bill does not mandate clear explainability or appeal rights if a transaction is wrongly suspended—creating risk of service delays or denial without full recourse.

Who stands to gain

• pharmaceutical companies (reduced fraudulent claims on their products)
• durable medical equipment suppliers (those with legitimate billing patterns)
• clinical diagnostic laboratories (those with legitimate billing patterns)
• Medicare program (reduced fraud payouts)

Named in the bill

Medicare, Department of Health and Human Services (HHS), Office of the Inspector General (OIG), Social Security Act Section 1128K, Executive Order 14179 (AI leadership), durable medical equipment suppliers, clinical diagnostic laboratories, Bristol Myers Squibb (BMY), Guardant Health (GH), Pfizer (PFE), DaVita (DVA), Johnson & Johnson (JNJ)

Where it stands

3 cosponsors: 2 Republicans, 1 Democrats.

• Jun 12, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Jun 12, 2025 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.